NCT06841757

Brief Summary

This randomized controlled study aims to evaluate the effects of Remote Ischemic Preconditioning (RIPC) on diastolic function in patients undergoing coronary artery bypass grafting (CABG). The study will compare diabetic and non-diabetic patients to determine whether RIPC improves myocardial relaxation and reduces diastolic dysfunction, as assessed by the E/e' ratio at multiple time points during the surgery.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at below P25 for not_applicable coronary-artery-disease

Timeline
Completed

Started Jan 2025

Shorter than P25 for not_applicable coronary-artery-disease

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2025

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

February 13, 2025

Completed
11 days until next milestone

First Posted

Study publicly available on registry

February 24, 2025

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2025

Completed
Last Updated

February 24, 2025

Status Verified

October 1, 2024

Enrollment Period

6 months

First QC Date

February 13, 2025

Last Update Submit

February 18, 2025

Conditions

Keywords

Coronary artery bypass surgeryDiastolic functionRemote ischemic preconditioning

Outcome Measures

Primary Outcomes (1)

  • E/e' Ratio (Diastolic Function)

    Echocardiography (Tissue Doppler Imaging) will be used to measure the E/e' ratio, a reliable parameter for assessing left ventricular filling pressure and diastolic function. This is the primary method to evaluate the effect of Remote Ischemic Preconditioning (RIPC) on diastolic function in both diabetic and non-diabetic patients undergoing CABG.

    T1: immediately after anesthesia induction and intubation (baseline) T2: Immediately before cardiopulmonary bypass (CPB) T3: 10 minutes after reperfusion and separation from CPB T4: 45 minutes after separation from CPB and before transfer to the ICU

Secondary Outcomes (6)

  • Mitral Inflow Velocities(E/A Ratio)

    T1: immediately after anesthesia induction and intubation (baseline) T2: Immediately before cardiopulmonary bypass (CPB) T3: 10 minutes after reperfusion and separation from CPB T4: 45 minutes after separation from CPB and before transfer to the ICU

  • Deceleration Time (DT)

    T1: immediately after anesthesia induction and intubation (baseline) T2: Immediately before cardiopulmonary bypass (CPB) T3: 10 minutes after reperfusion and separation from CPB T4: 45 minutes after separation from CPB and before transfer to the ICU

  • Cardiac Troponin Levels

    Evaluate cardiac troponin levels postoperatively after 24 hours as a marker of myocardial injury

  • Systolic and diastolic Blood pressure

    T1: immediately after anesthesia induction and intubation (baseline) T2: Immediately before cardiopulmonary bypass (CPB) T3: 10 minutes after reperfusion and separation from CPB T4: 45 minutes after separation from CPB and before transfer to the ICU

  • Inotropic Support:

    During surgery

  • +1 more secondary outcomes

Study Arms (4)

Diabetic with Remote ischemic preconditioning

EXPERIMENTAL

Remote Ischemic Preconditioning (RIPC) Patients will undergo Remote Ischemic Preconditioning using a blood pressure cuff inflated on the upper limb to induce ischemia and reperfusion, 40 mmHg above systolic pressure. The procedure will involve 3 cycles of inflation (5 minutes each) and deflation (5 minutes each) post intubation.

Behavioral: Remote ischemic preconditioning

Non diabetic with Remote ischemic preconditioning

EXPERIMENTAL

Remote Ischemic Preconditioning (RIPC) Non-diabetic patients who undergo Remote ischemic preconditioning using the same ischemia/reperfusion protocol as the diabetic group.

Behavioral: Remote ischemic preconditioning

Diabetic without Remote ischemic preconditioning

NO INTERVENTION

Diabetic patients who receive standard care for CABG surgery without Remote ischemic preconditioning

Non diabetic without Remote ischemic preconditioning

NO INTERVENTION

Non-diabetic patients who receive standard care for CABG surgery without RIPC.

Interventions

Patients will undergo Remote Ischemic Preconditioning using a blood pressure cuff inflated on the upper limb to induce ischemia and reperfusion, 40 mmHg above systolic pressure. The procedure will involve 3 cycles of inflation (5 minutes each) and deflation (5 minutes each) post intubation

Diabetic with Remote ischemic preconditioningNon diabetic with Remote ischemic preconditioning

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All adult patients scheduled for elective isolated on-pump CABG surgery for two- to three-vessel coronary artery disease.
  • Both males and females will be included.
  • In the diabetic groups: Type II diabetes currently requiring and adhering to insulin therapy for at least the past 3 months
  • During cardiopulmonary bypass, the temperature will range from 28-33°C using an esophageal temperature probe.
  • Antegrade warm cardioplegia will be given by the cardiovascular perfusionist.
  • Baseline diastolic function will be obtained preoperatively using transthoracic echocardiography done within the six months prior to the surgery

You may not qualify if:

  • Combined CABG and valve surgery, emergency CABG.
  • Type I diabetes, Type 2 diabetes managed with oral hypoglycemic agents without insulin in the past 3 months
  • Peripheral vascular disease (PVD) affecting the upper limbs.
  • Acute coronary syndrome (ACS); acute or recent myocardial infarction.
  • Left ventricular ejection fraction ≤30%.
  • Serious pulmonary disease necessitating oxygen supplementation or mechanical ventilation.
  • Renal failure, defined as eGFR \< 30 mL/min/1.73 m² or requiring renal replacement therapy (dialysis).
  • Liver failure, including Child-Pugh Class B or C cirrhosis, severe hepatocellular dysfunction, or listed for liver transplantation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cairo university hospital

Cairo, Egypt

Location

Related Publications (1)

  • Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M, DeCleene N, Eagle KA, Emmons-Bell S, Feigin VL, Fernandez-Sola J, Fowkes G, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum N, Koroshetz W, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Temesgen AM, Mokdad A, Moran AE, Muntner P, Narula J, Neal B, Ntsekhe M, Moraes de Oliveira G, Otto C, Owolabi M, Pratt M, Rajagopalan S, Reitsma M, Ribeiro ALP, Rigotti N, Rodgers A, Sable C, Shakil S, Sliwa-Hahnle K, Stark B, Sundstrom J, Timpel P, Tleyjeh IM, Valgimigli M, Vos T, Whelton PK, Yacoub M, Zuhlke L, Murray C, Fuster V; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010.

    PMID: 33309175BACKGROUND

MeSH Terms

Conditions

Coronary Artery DiseaseDiabetes Mellitus

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular DiseasesGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Ahmed Alagaty Ehsan Alagaty, Professor of anesthesia

    Cairo University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Assistant lecturer in Cairo university

Study Record Dates

First Submitted

February 13, 2025

First Posted

February 24, 2025

Study Start

January 1, 2025

Primary Completion

July 1, 2025

Study Completion

July 1, 2025

Last Updated

February 24, 2025

Record last verified: 2024-10

Data Sharing

IPD Sharing
Will not share

Locations